Further research could also help explain and even predict variation in the onset of behavioral changes in people with ...

In two papers, published in Cell and Science, they demonstrate how utilizing the unique capabilities of a protein called TRIM21 gives the potential therapies two key advantages. Firstly, they only ...

When most people think of dementia, particularly Alzheimer’s disease, they often think of memory loss first. However, ...

Researchers have discovered that disruptions in the brain’s salience network, often tied to tau protein buildup, correlate strongly with behavioral changes in people with early-stage dementia.

Researchers from the University of Michigan reveal new insights into early-stage dementia, identifying tau protein as a ...

GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson’s Disease ModelsGT-02287 Improves Mitochondrial Function ...

The drug is RI-AG03, and it's a peptide inhibitor (a blocker of proteins). In tests on fruit flies and human cells, it has ...

A peptide inhibitor called RI-AG03 targets major aggregation “hot spots” of tau proteins, believed to be a key driver of ...

DEPTAC. Based on PROTACs, or protein-targeting chimeras, D20, a dephosphorylation-targeting chimera, delivers PP1 to tau. The C-terminal tail (gray) helps the construct enter cells. [Courtesy of Xiao ...

Scientists say they have achieved a "first" in the development of drugs to treat Alzheimer's disease. In a study published in the journal Alzheimer's & Dementia, a team of researchers report the ...

An international team of researchers led by Lancaster University have made a promising breakthrough in the development of drugs to treat Alzheimer’s Disease. For the first time, scientists have ...